The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Open accessAbstract
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and the leading cause of chronic liver disease in the Western world. Twenty per cent of NAFLD individuals develop chronic hepatic inflammation (non-alcoholic steatohepatitis, NASH) associated with cirrhosis, portal hypertension and hepatocellular carcinoma, yet the causes of progression from NAFLD to NASH remain obscure. Here, we show that the NLRP6 and NLRP3 inflammasomes and the effector protein IL-18 negatively regulate NAFLD/NASH progression, as well as multiple aspects of metabolic syndrome via modulation of the gut microbiota. Different mouse models reveal that inflammasome-deficiency-associated changes in the configuration of the gut microbiota are associated with exacerbated hepatic steatosis and inflammation through influx of TLR4 and TLR9 agonists into the portal circulation, leading to enhanced hepatic tumour-necrosis factor (TNF)-α expression that drives NASH progression. Furthermore, co-housing of inflammasome-deficient mice with wild-type mice results in exacerbation of hepatic steatosis and obesity. Thus, altered interactions between the gut microbiota and the host, produced by defective NLRP3 and NLRP6 inflammasome sensing, may govern the rate of progression of multiple metabolic syndrome-associated abnormalities, highlighting the central role of the microbiota in the pathogenesis of heretofore seemingly unrelated systemic auto-inflammatory and metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LPS-mediated activation of KCs via TLR4 leading to MyD88-dependent activation of NF-kB, production of proinflammatory cytokines and subsequent liver injury have also been demonstrated for both MASH(214) and ASH(215).”
From The liver as a central "hub" of the immune system: pathophysiological implications (2025) · cites this paper as [214]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Animal studies have demonstrated a direct role of altered intestinal microbiota in steatosis,15 NASH(16), fibrosis17 and liver cancer.18”
From Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling (2023) · cites this paper as [16]
In the citing paper
“In NAFLD models, lack of inflammasomes has been demonstrated to select a pathogenetic microbiota which was associated with a more severe degree of liver injury [226].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [226]
In the citing paper
“Either in patients with NASH or animal models, the expression of inflammasome components was increased, indicating the potential role in the pathogenesis of liver injury [226,227,288,289,290,291].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [226]
In the citing paper
“These results indicate that complex interactions between the diet, the innate immunity, bacteria and intestinal function occurs in the development of NASH [226,227], and similar observations were obtained in experimental models of HCC development [285,286,287].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [226]
In the citing paper
“Co-housing wildtype mice with mice prone to MASH led to increased disease severity in wildtype mice, presumably due to a transfer of fecal microbiota (204).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [204]
In the citing paper
“In the MCD diet model, the microbiota has a key role in NASH exacerbation as demonstrated by experiments, in which co-housing transmitted NASH risk and antibiotics reduced NASH risk65.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [65]
In the citing paper
“Functional studies utilizing co-housing and faecal transplantation have provided evidence that dysbiosis is a transmissible driver of liver disease development and progression 65,89.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [65]
In the citing paper
“Similarly, dysbiosis represented a transmissible risk factor in a genetic NASH model in which NASH was triggered by inflammasome deficiency; co-housing of dysbiotic inflammasome-deficient mice with control mice resulted in the development of NASH in control mice65.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [65]
In the citing paper
“Association of bacterial composition with many diseases has been observed, including immune, inflammatory, and metabolic phenotypes.”
From The Gut Microbiome Contributes to a Substantial Proportion of the Variation in Blood Lipids (2015) · cites this paper as [5]
In the citing paper
“Disruption of the murine inflammasomes (see box 1) is associated with an increase in Bacteroidetes and reduction in Firmicutes and results in severe hepatic steatosis and inflammation.41”
From The gut microbiota and host health: a new clinical frontier (2016) · cites this paper as [41]
In the citing paper
“the NLRP6 and NLRP3 inflammasomes may exert protective effects against NAFLD/NASH through modulation of the gut microbiota.181”
From Interaction between microbiota and immunity in health and disease (2020) · cites this paper as [181]
In the citing paper
“Dysbiosis has been observed in mice deficient for inflammasomes components, including NLRP6, ASC, caspase-1, and IL-18 [131,132,133,134].”
From Gut Microbiota and Cancer: From Pathogenesis to Therapy (2019) · cites this paper as [134]
In the citing paper
“The Muc2-KO mouse possesses a distinct gut-associated bacterial community that is influenced by its altered genetic and immune states, as has been shown in other genetic knockout mouse models.4,53–55”
From Using Corticosteroids to Reshape the Gut Microbiome: Implications for Inflammatory Bowel Diseases (2015) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
Self-citationDesign and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 1×
“Tlr9 –/– mice have been described in another repor”
BackgroundMartinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066
A role for mitochondria in nlrp3 inflammasome activation
Zhou, R., Yazdi, A. S., Menu, P., & Tschopp, J. (2011) · Nature · doi:10.1038/nature09663 · Cited by 5,602
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,728
Thioredoxin-interacting protein links oxidative stress to inflammasome activation
Zhou, R., Tardivel, A., Thorens, B., Choi, I., & Tschopp, J. (2010) · Nature Immunology · doi:10.1038/ni.1831 · Cited by 2,708
Cited by
Sorted by citations
Items 201–300 of 1,011
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions
Lonardo, A., Nascimbeni, F., Targher, G., Bernardi, M., Bonino, F., Bugianesi, E., Casini, A., Gastaldelli, A., Marchesini, G., Marra, F., et al. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2017.01.147 · Cited by 313
The NLRP6 Inflammasome Recognizes Lipoteichoic Acid and Regulates Gram-Positive Pathogen Infection
Hara, H., Seregin, S. S., Yang, D., Fukase, K., Chamaillard, M., Alnemri, E. S., Inohara, N., Chen, G., & Núñez, G. (2018) · Cell · doi:10.1016/j.cell.2018.09.047 · Cited by 315
The neurobiology of food intake in an obesogenic environment
Berthoud, H. (2012) · Proceedings of The Nutrition Society · doi:10.1017/s0029665112000602 · Cited by 319
Dynamics of Gut Microbiota in Autoimmune Lupus
Zhang, H., Liao, X., Sparks, J. B., & Luo, X. (2014) · Applied and Environmental Microbiology · doi:10.1128/aem.02676-14 · Cited by 308
Inflammasomes in the gastrointestinal tract: infection, cancer and gut microbiota homeostasis
Man, S. M. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0054-1 · Cited by 315
Freigang, S., Ampenberger, F., Weiss, A., Kanneganti, T., Iwakura, Y., Hersberger, M., & Köpf, M. (2013) · Nature Immunology · doi:10.1038/ni.2704 · Cited by 313
Beneficial Effects of Betaine: A Comprehensive Review
Arumugam, M. K., Paal, M. C., Donohue, T. M., Ganesan, M., Osna, N. A., & Kharbanda, K. K. (2021) · Biology · doi:10.3390/biology10060456 · Cited by 313
Dzutsev, A., Badger, J. H., Perez-Chanona, E., Roy, S., Salcedo, R., Smith, C. K., & Trinchieri, G. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052133 · Cited by 302
Specific Gut Microbiome Signature Predicts the Early-Stage Lung Cancer
Zheng, Y., Fang, Z., Xue, Y., Zhang, J., Zhu, J., Gao, R., Yao, S., Ye, Y., Wang, S., Lin, C., et al. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1737487 · Cited by 301
Cell Death in Liver Diseases: A Review
Shojaie, L., Iorga, A., & Dara, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249682 · Cited by 309
Vallianou, N. G., Christodoulatos, G. S., Karampela, Ι., Tsilingiris, D., Magkos, F., Stratigou, T., Kounatidis, D. C., & Dalamaga, Μ. (2021) · Biomolecules · doi:10.3390/biom12010056 · Cited by 305
Inflammasomes on the Crossroads of Innate Immune Recognition and Metabolic Control
Próchnicki, T., & Latz, E. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.06.018 · Cited by 302
The Inflammasomes and Autoinflammatory Syndromes
Broderick, L., Nardo, D. D., Franklin, B. S., Hoffman, H. M., & Latz, E. (2014) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040431 · Cited by 304
Self-citationHorst, A. K., Neumann, K., Diehl, L., & Tiegs, G. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.112 · Cited by 295
NLRP3 at the interface of metabolism and inflammation
Haneklaus, M., & O'Neill, L. A. J. (2015) · Immunological Reviews · doi:10.1111/imr.12285 · Cited by 296
Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice
Ritze, Y., Bárdos, G., Claus, A., Ehrmann, V., Bergheim, I., Schwiertz, A., & Bischoff, S. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0080169 · Cited by 292
A concise review of non-alcoholic fatty liver disease
Than, N. N., & Newsome, P. N. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.001 · Cited by 296
Hu, H., Shao, W., Liu, Q., Liu, N., Wang, Q., Xu, J., Zhang, X., Weng, Z., Lu, Q., Jiao, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27758-8 · Cited by 288
Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability
Luther, J., Garber, J. J., Khalili, H., Dave, M., Bale, S. S., Jindal, R., Motola, D. L., Luther, S., Bohr, S., Jeoung, S. W., et al. (2015) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2015.01.001 · Cited by 286
Hong, Y., Sheng, L., He, X., Zhong, J., Ma, J., 赵爱华, Zheng, X., Gu, Y., Yao, J., Li, Y., et al. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1930874 · Cited by 287
Miura, K., Yang, L., van Rooijen, N., Brenner, D. A., Ohnishi, H., & Seki, E. (2012) · Hepatology · doi:10.1002/hep.26081 · Cited by 290
Role of the Inflammasome in Liver Disease
Ribeiro, M. D. C., & Szabó, G. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-032521-102529 · Cited by 286
Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice
De Minicis, S., Rychlicki, C., Agostinelli, L., Saccomanno, S., Candelaresi, C., Trozzi, L., Mingarelli, E., Facinelli, B., Magi, G., Palmieri, C., et al. (2014) · Hepatology · doi:10.1002/hep.26695 · Cited by 279
Tseng, C.-H., & Wu, C. (2018) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.07.009 · Cited by 286
Tokushige, K., Ikejima, K., Ono, M., Eguchi, Y., Kamada, Y., Itoh, Y., Akuta, N., Yoneda, M., Iwasa, M., Yoneda, M., et al. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-021-01796-x · Cited by 282
The Role of Probiotics and Prebiotics in Inducing Gut Immunity
Vieira, A. T., Teixeira, M. M., & Martins, F. S. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00445 · Cited by 284
van den Munckhof, I., Kurilshikov, A., ter Horst, R., Riksen, N. P., Joosten, L. A. B., Zhernakova, A., Fu, J., Keating, S. T., Netea, M. G., Graaf, J. D., et al. (2018) · Obesity Reviews · doi:10.1111/obr.12750 · Cited by 281
McCabe, L. R., Irwin, R., Schaefer, L., & Britton, R. A. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24340 · Cited by 285
Antibiotics promote inflammation through the translocation of native commensal colonic bacteria
Knoop, K. A., McDonald, K. G., Kulkarni, D. H., & Newberry, R. D. (2015) · Gut · doi:10.1136/gutjnl-2014-309059 · Cited by 284
The Role of Gut Microbiota on Insulin Resistance
Caricilli, A. M., & Saad, M. A. (2013) · Nutrients · doi:10.3390/nu5030829 · Cited by 285
Apoptosis and non-alcoholic fatty liver diseases
Kanda, T., Matsuoka, S., Yamazaki, M., Shibata, T., Nirei, K., Takahashi, H., Kaneko, T., Fujisawa, M., Higuchi, T., Nakamura, H., et al. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i25.2661 · Cited by 269
T cell responses in the central nervous system
Korn, T., & Kallies, A. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.144 · Cited by 268
Microbiome, inflammation and colorectal cancer
Chen, J., Pitmon, E., & Wang, K. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.006 · Cited by 274
Probiotics modulate gut microbiota and improve insulin sensitivity in DIO mice
Bagarolli, R. A., Tobar, N., Oliveira, A. G., Araújo, T. G., Carvalho, B. M., Rocha, G. Z., Vecina, J. F., Calisto, K., Guadagnini, D., Prada, P. O., et al. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.08.006 · Cited by 266
Pathways in Microbe-Induced Obesity
Cox, L. M., & Blaser, M. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.004 · Cited by 272
Does lipopolysaccharide-mediated inflammation have a role in OA?
Huang, Z., & Kraus, V. B. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.158 · Cited by 265
The gut microbiota: A treasure for human health
Li, D., Wang, P., Wang, P., Hu, X., & Chen, F. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.08.003 · Cited by 271
Alteration of the gut microbiota in Chinese population with chronic kidney disease
Jiang, S., Xie, S., Lv, D., Wang, P., He, H., Zhang, T., Zhou, Y., Lin, Q., Zhou, H., Jiang, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02989-2 · Cited by 269
Daily eating patterns and their impact on health and disease
Zarrinpar, A., Chaix, A., & Panda, S. (2016) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.11.007 · Cited by 263
Wang, X., He, Q., Zhou, C., Xu, Y., Liu, D., Fujiwara, N., Kubota, N., Click, A., Henderson, P., Vancil, J., et al. (2023) · Immunity · doi:10.1016/j.immuni.2022.11.013 · Cited by 262
Microbial modulation of insulin sensitivity
Khan, M. T., Nieuwdorp, M., & Bäckhed, F. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.07.006 · Cited by 260
Mira‐Pascual, L., Cabrera‐Rubio, R., Ocon, S. M., Costales, P., Parra, A., Suárez, A., Morís, F., Rodrigo, L., Mira, Á., & Collado, M. C. (2014) · Journal of Gastroenterology · doi:10.1007/s00535-014-0963-x · Cited by 269
Cho, Y., Kim, D., Seo, W., Gao, B., Yoo, S., & Song, B. (2019) · Hepatology · doi:10.1002/hep.30652 · Cited by 266
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Lee, K., Wu, P.-S., & Lin, H. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0237 · Cited by 269
The importance of the gut microbiota after bariatric surgery
Aron‐Wisnewsky, J., Dore, J. M., & Clément, K. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.161 · Cited by 271
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis
Adorini, L., Pruzanski, M., & Shapiro, D. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.012 · Cited by 259
Llorente, C., Jepsen, P., Inamine, T., Wang, L., Bluemel, S., Wang, H. J., Loomba, R., Bajaj, J. S., Schubert, M. L., Sikaroodi, M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00796-x · Cited by 257
Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches
Schuppan, D., & Schattenberg, J. M. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12212 · Cited by 256
Tanwar, S., Rhodes, F., Srivastava, A., Trembling, P. M., & Rosenberg, W. M. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i2.109 · Cited by 261
IL-17 Signaling Accelerates the Progression of Nonalcoholic Fatty Liver Disease in Mice
Harley, I. T. W., Stankiewicz, T. E., Giles, D. A., Softic, S., Flick, L. M., Cappelletti, M., Sheridan, R. M., Xanthakos, S. A., Steinbrecher, K. A., Sartor, R. B., et al. (2013) · Hepatology · doi:10.1002/hep.26746 · Cited by 257
Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease
Svegliati‐Baroni, G., Pierantonelli, I., Torquato, P., Marinelli, R., Ferreri, C., Chatgilialoglu, C., Bartolini, D., & Galli, F. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.05.029 · Cited by 255
Gut microbiota and metabolic syndrome
Wang, P.-X., Deng, X., Zhang, C., & Yuan, H. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000696 · Cited by 266
Gut microbiota and non-alcoholic fatty liver disease: new insights
Aron‐Wisnewsky, J., Gaborit, B., Dutour, A., & Clément, K. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12140 · Cited by 257
Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic
Mendrick, D. L., Diehl, A. M., Topor, L. S., Dietert, R. R., Will, Y., Merrill, M. A. L., Bouret, S. G., Varma, V., Hastings, K. L., Schug, T. T., et al. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx233 · Cited by 262
Linking the Microbiota, Chronic Disease, and the Immune System
Hand, T. W., Vujkovic-Cvijin, I., Ridaura, V. K., & Belkaid, Y. (2016) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.08.003 · Cited by 247
The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk
Caussy, C., Aubin, A., & Loomba, R. S. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01383-7 · Cited by 253
Gut microbiota, host health, and polysaccharides
Xu, X., Xu, P., Ma, C., Tang, J., & Zhang, X. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.12.009 · Cited by 249
Putignani, L., CHIERICO, F. D., Petrucca, A., Vernocchi, P., & Dallapiccola, B. (2014) · Pediatric Research · doi:10.1038/pr.2014.49 · Cited by 249
Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?
Aron‐Wisnewsky, J., Warmbrunn, M. V., Nieuwdorp, M., & Clément, K. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.049 · Cited by 252
Heyens, L. J. M., Busschots, D., Koek, G. H., Robaeys, G., & Francque, S. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.615978 · Cited by 258
Non-alcoholic fatty liver and the gut microbiota
Bashiardes, S., Shapiro, H., Rozin, S., Shibolet, O., & Elinav, E. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.06.003 · Cited by 241
Self-citationInflammasome Priming in Sterile Inflammatory Disease
Patel, M. N., Carroll, R. G., Galván-Peña, S., Mills, E. L., Olden, R., Triantafilou, M., Wolf, A. I., Bryant, C. E., Triantafilou, K., & Masters, S. L. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.12.007 · Cited by 241
Cândido, F. G., Valente, F. X., Grześkowiak, Ł., Moreira, A. P. B., Rocha, D. M. U. P., & Alfenas, R. D. C. G. (2017) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2017.1343286 · Cited by 248
Modulatory Mechanisms of the NLRP3 Inflammasomes in Diabetes
Ding, S., Xu, S., Ma, Y., Liu, G., Jang, H., & Fang, J. Q. (2019) · Biomolecules · doi:10.3390/biom9120850 · Cited by 246
Pyrazolone structural motif in medicinal chemistry: Retrospect and prospect
Zhao, Z., Dai, X., Li, C., Wang, X. L., Tian, J., Feng, Y., Xie, J., Ma, C., Nie, Z., Fan, P., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111893 · Cited by 240
Zhang, X., Zhang, J.-H., Chen, X.-Y., Hu, Q., Wang, M., Jin, R., Zhang, Q., Wang, W., Wang, R., Kang, L.-L., et al. (2015) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.5868 · Cited by 240
Microbiota-mediated inflammation and antimicrobial defense in the intestine
Caballero, S., & Pamer, E. G. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120238 · Cited by 238
MECHANISMS IN ENDOCRINOLOGY: Gut microbiota in patients with type 2 diabetes mellitus
Allin, K. H., Nielsen, T., & Pedersen, O. B. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0874 · Cited by 243
Ramakrishna, G., Rastogi, A., Trehanpati, N., Sen, B., Khosla, R., & Sarin, S. K. (2013) · Liver Cancer · doi:10.1159/000343852 · Cited by 244
Harjumäki, R., Pridgeon, C. S., & Ingelman‐Sundberg, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158221 · Cited by 248
Gut Microbiota Metabolism and Interaction with Food Components
Vernocchi, P., CHIERICO, F. D., & Putignani, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103688 · Cited by 242
Therapeutic Modulation of Microbiota-Host Metabolic Interactions
Holmes, E. C., Kinross, J. K., Gibson, G. R., Burcelin, R., Jia, W. P., Pettersson, S., & Nicholson, J. K. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004244 · Cited by 237
Wu, T., Zhang, Z., Liu, B., Hou, D., Liang, Y., Zhang, J., & Shi, P. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-669 · Cited by 234
The Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. E. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 236
Straub, R. H., & Carsten Schradin, A. (2016) · Evolution Medicine and Public Health · doi:10.1093/emph/eow001 · Cited by 244
The microbiome and autoimmunity: a paradigm from the gut–liver axis
Li, B., Selmi, C. F., Tang, R., Gershwin, M. E., & Ma, X. (2018) · Cellular and Molecular Immunology · doi:10.1038/cmi.2018.7 · Cited by 237
Microbiota and Fatty Liver Disease—the Known, the Unknown, and the Future
Lang, S., & Schnabl, B. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.07.007 · Cited by 244
Gut–liver axis, cirrhosis and portal hypertension: the chicken and the egg
Arab, J. P., Martín‐Mateos, R., & Shah, V. H. (2017) · Hepatology International · doi:10.1007/s12072-017-9798-x · Cited by 233
Truax, A. D., Chen, L., Tam, J. W., Cheng, N., Guo, H., Koblansky, A. A., Chou, W.-C., Wilson, J. E., Brickey, W. J., Petrucelli, A., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.08.009 · Cited by 228
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
The microbiota-immune axis as a central mediator of gut-brain communication
Fung, T. C. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104714 · Cited by 234
An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease
Lee, E., Korf, H., & Vidal‐Puig, A. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.01.024 · Cited by 235
Nesci, A., Carnuccio, C., Ruggieri, V., D’Alessandro, A., Giorgio, A. D., Santoro, L., Gasbarrini, A., Santoliquido, A., & Ponziani, F. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109087 · Cited by 235
The Role of Gut Microbiota in Atherosclerosis and Hypertension
Ma, J., & Li, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01082 · Cited by 234
Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Parola, M., & Pinzani, M. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101231 · Cited by 239
Schneider, K. M., Mohs, A., Gui, W., Galvez, E. J. C., Candels, L. S., Hoenicke, L., Muthukumarasamy, U., Holland, C. H., Elfers, C., Kilic, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31312-5 · Cited by 225
Self-citationLytic cell death in metabolic liver disease
Gautheron, J., Gores, G. J., & Rodrigues, C. M. P. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.001 · Cited by 225
Herbal drug discovery for the treatment of nonalcoholic fatty liver disease
Yan, T., Yan, N., Wang, P., Xia, Y., Hao, H., Wang, G., & Gonzalez, F. J. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.11.017 · Cited by 226
Intestinal microbiome and fitness in kidney disease
Meijers, B. K. I., Evenepoel, P., & Anders, H. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0172-1 · Cited by 228
Metabolic drivers of non-alcoholic fatty liver disease
Bence, K. K., & Birnbaum, M. J. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101143 · Cited by 230
Huo, R., Zeng, B., Zeng, L., Cheng, K., Li, B., Luo, Y., Wang, H., Zhou, C., Fang, L., Li, W., et al. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00489 · Cited by 221
The NLR gene family: from discovery to present day
Chou, W.-C., Jha, S., Linhoff, M. W., & Ting, J. P. ‐. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00849-x · Cited by 232
Endotoxemia—menace, marker, or mistake?
Munford, R. S. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ru0316-151r · Cited by 219
Koda, Y., Teratani, T., Chu, P.-S., Hagihara, Y., Mikami, Y., Harada, Y., Tsujikawa, H., Miyamoto, K., Suzuki, T., Taniki, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24734-0 · Cited by 219
Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame
Ibrahim, S. H., Hirsova, P., Malhi, H., & Gores, G. J. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3977-1 · Cited by 218
Amar, J., Lange, C., Payros, G., Garret, C., Chabo, C., Lantieri, O., Courtney, M., Marre, M., Charles, M.-A. A., Balkau, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054461 · Cited by 222
Non-caloric artificial sweeteners and the microbiome: findings and challenges
Suez, J., Korem, T., Zilberman-Schapira, G., Segal, E., & Elinav, E. (2015) · Gut Microbes · doi:10.1080/19490976.2015.1017700 · Cited by 217
Self-citationLinks between metabolic syndrome and metabolic dysfunction-associated fatty liver disease
Lim, S. K., Kim, J., & Targher, G. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.04.008 · Cited by 224
Plasma Lipopolysaccharide Is Closely Associated With Glycemic Control and Abdominal Obesity
Trøseid, M., Nestvold, T. K., Rudi, K., Thoresen, H., Nielsen, E. W., & Lappegård, K. T. (2013) · Diabetes Care · doi:10.2337/dc13-0451 · Cited by 223
Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis
Weston, C. J., Shepherd, E. L., Claridge, L. C., Rantakari, P., Curbishley, S. M., Tomlinson, J., Hübscher, S. G., Reynolds, G. M., Aalto, K., Anstee, Q. M., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73722 · Cited by 214
Metadata
- Authors
- Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., Camporez, J.-P., Shulman, G. I., Gordon, J. I., Hoffman, H. M., & Flavell, R. A.
- Affiliations
- Yale University (US)
- Washington University in St. Louis (US)
- Howard Hughes Medical Institute (US)
- University of California San Diego (US)
- Corresponding author
- Flavell, Richard A.
- ORCID
- Venue
- Nature
- Published
- 2012-02
- Volume
- 482
- Issue
- 7384
- Pages
- 179-185
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3276682
- OpenAlex
- W2144275312
- Cited by
- 2,435
- References
- 41
- Citations by year
- 2026: 83 · 2025: 103 · 2024: 137 · 2023: 165 · 2022: 158 · 2021: 182 · 2020: 215 · 2019: 188 · 2018: 197 · 2017: 184 · 2016: 172 · 2015: 195 · 2014: 181 · 2013: 185 · 2012: 85
- FWCI
- 154.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Crohn's and Colitis Foundation
- U.S. Public Health Service (K08A1085038)
- National Heart, Lung, and Blood Institute (T32HL007974)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK45735, R01-DK40936, R01DK040936, U24DK059635, R01DK076674, R24DK085638, P30DK045735)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, NLRP3 inflammasome, NLRP6 inflammasome, IL-18, gut dysbiosis, metabolic syndrome, obesity, hepatic steatosis, liver inflammation, TLR4, TLR9, TNF-α, Porphyromonadaceae, host-microbiota interactions, autoinflammatory disease
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Carrier Proteins, Choline, Colon, Cytoskeletal Proteins, Disease Models, Animal, Fatty Liver, Inflammation, Male, Methionine, Mice, Inbred C57BL, Obesity, Receptors, Cell Surface, RNA, Ribosomal, 16S, Tumor Necrosis Factor-alpha, Disease Progression, Interleukin-18, Apoptosis Regulatory Proteins, Toll-Like Receptor 4, Toll-Like Receptor 9, Mice, CARD Signaling Adaptor Proteins, Metagenome, Inflammasomes, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
